On December 10, 2025, Amplex AB announced a cash offer to the shareholders and warrant holders of ADDvise Group AB (publ) (“ADDvise”) to acquire all outstanding shares and warrants in ADDvise.
At the end of the extended acceptance period on February 17, 2026, Amplex owns approximately 99.35 percent of the share capital and approximately 99.01 percent of the votes in ADDvise, as well as 95.11 percent of the outstanding warrants.
The offer is now closed. The shares and warrants in ADDvise have been delisted from Nasdaq First North. The last day of trading in the shares and warrants was February 17, 2026. Amplex has invoked compulsory redemption in accordance with the Swedish Companies Act (2005:551) to acquire all remaining shares in ADDvise.
We therefore warmly welcome ADDvise, with all its subsidiaries and employees, to the Amplex Group!
ADDvise Group is an international life science group comprising some 20 operating companies, dedicated to providing premium products and services to the healthcare and research sectors. ADDvise has around 625 employees in the US, Sweden, Finland, the Netherlands, Ireland, the United Arab Emirates, and Brazil.
Addvise is now forming its own business area within Amplex, led by Staffan Torstensson, Business Area Manager and CEO of ADDvise Group.
Fredrik Celsing, President and CEO of Amplex, says: “I am very pleased that ADDvise is now part of the Amplex family. Through ADDvise, we are adding a large number of well-managed companies with strong positions in interesting niche markets. It will be exciting to continue working together to strengthen and develop the ADDvise companies and create new successes.”
For more information about ADDvise and its member companies, please visit www.addvisegroup.se.
Read the full press release here:
Amplex AB announces final outcome